A new COVID-19 vaccine developed by China's Sinopharm has recently been approved for clinical trials.
The new recombinant COVID-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D center of Sinopharm's bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday (April 10).
China
04-11 16:55:02